Legal & General Group’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,120
Closed -$109K 3649
2022
Q1
$109K Hold
1,120
﹤0.01% 2844
2021
Q4
$183K Buy
1,120
+582
+108% +$128K ﹤0.01% 2757
2021
Q3
$146K Buy
538
+283
+111% +$86.5K ﹤0.01% 2771
2021
Q2
$102K Sell
255
-13
-5% -$6.07K ﹤0.01% 2726
2021
Q1
$145K Buy
268
+43
+19% +$26.8K ﹤0.01% 2518
2020
Q4
$85K Sell
225
-63
-22% -$25.1K ﹤0.01% 2631
2020
Q3
$109K Sell
288
-64
-18% -$28.3K ﹤0.01% 2464
2020
Q2
$173K Buy
352
+18
+5% +$8.03K ﹤0.01% 2386
2020
Q1
$122K Buy
334
+44
+15% +$22.8K ﹤0.01% 2360
2019
Q4
$205K Buy
290
+44
+18% +$30.3K ﹤0.01% 2394
2019
Q3
$158K Buy
246
+41
+20% +$32.5K ﹤0.01% 2402
2019
Q2
$179K Buy
205
+33
+19% +$22.7K ﹤0.01% 2375
2019
Q1
$99K Hold
172
﹤0.01% 2488
2018
Q4
$48K Buy
172
+40
+30% +$15.8K ﹤0.01% 2713
2018
Q3
$63K Sell
132
-88
-40% -$37.7K ﹤0.01% 2664
2018
Q2
$100K Sell
220
-23
-9% -$14.6K ﹤0.01% 2501
2018
Q1
$143K Sell
243
-70
-22% -$43.6K ﹤0.01% 2381
2017
Q4
$193K Hold
313
﹤0.01% 2327
2017
Q3
$289K Buy
313
+15
+5% +$13.3K ﹤0.01% 2225
2017
Q2
$279K Buy
298
+18
+6% +$17.6K ﹤0.01% 2193
2017
Q1
$267K Sell
280
-3
-1% -$2.79K ﹤0.01% 2178
2016
Q4
$227K Buy
283
+79
+39% +$71.2K ﹤0.01% 2198
2016
Q3
$173K Sell
204
-10
-5% -$8.04K ﹤0.01% 2071
2016
Q2
$177K Hold
214
﹤0.01% 1824
2016
Q1
$237K Buy
214
+65
+44% +$66.5K ﹤0.01% 1675
2015
Q4
$184K Hold
149
﹤0.01% 1779
2015
Q3
$203K Buy
149
+39
+35% +$64.4K ﹤0.01% 1698
2015
Q2
$197K Buy
110
+6
+6% +$9.31K ﹤0.01% 1756
2015
Q1
$175K Hold
104
﹤0.01% 1737
2014
Q4
$81K Hold
104
﹤0.01% 2126
2014
Q3
$42K Buy
+104
New +$50.1K ﹤0.01% 2483

Other funds holding TCRT

Legal & General Group's TCRT Position: Q2 2022 in Review

Legal & General Group sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 1,120 shares — an estimated $109K sold.

Legal & General Group first reported a position in TCRT in Q3 2014 and held it in 31 quarters. The position peaked at $289K in Q3 2017. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Legal & General Group reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 1,120 Alaunos Therapeutics shares in Q2 2022, an estimated $109K.
  • Legal & General Group first reported a position in Alaunos Therapeutics in Q3 2014 and held it in 31 quarters.
  • Legal & General Group's Alaunos Therapeutics position peaked at $289K in Q3 2017.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.